Home LiteratureArticle Details
PMID: 17616708 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor.

Cancer research ·Vol. 67 ·No. 13 ·2007-07-01 ·Pages 6468-76

Zhang P, Côté AL, de Vries VC, Usherwood EJ, Turk MJ

Abstract

The generation of protective CD8 T-cell memory against tumor-expressed self-antigens is an important but elusive goal of cancer immunotherapy. The possibility that a progressive, poorly immunogenic tumor can induce T-cell memory against self-antigens has not previously been studied. Herein, we report that growth of the poorly immunogenic B16 melanoma in the absence of regulatory T cells (T(reg)) generates CD8 T-cell responses that develop into functional memory after the tumor has been surgically excised. Tumor-primed memory T cells recognized melanocyte differentiation antigens TRP-2/DCT and gp100 and persisted for as long as 5 months following surgical tumor excision. Phenotypic analysis showed that these cells develop into both central and effector memory T-cell subsets, which produce IFN-gamma and interleukin-2 on reencounter with antigen. Most importantly, tumor-primed memory T cells mediated the rejection of intradermal and systemically disseminated challenge tumors given 30 to 60 days following surgery. Tumor-excised mice also developed autoimmune vitiligo, showing that T(reg) cells prevent tissue-specific autoimmunity in tumor-bearing hosts. This study establishes that T(reg) depletion in tumor-bearing hosts drives the natural development of protective T-cell memory. Generating such responses may aid in the clinical management of tumor recurrence and metastasis following surgery.

MeSH Terms
Animals Autoimmune Diseases/immunology CD4-Positive T-Lymphocytes/metabolism Cytokines/metabolism Immunologic Memory Immunotherapy/methods Interferon-gamma/metabolism Interleukin-2/metabolism Male Melanoma, Experimental/immunology,pathology Mice Mice, Inbred C57BL Postoperative Period T-Lymphocytes/immunology,metabolism Vitiligo/immunology
Chemicals
Cytokines Interleukin-2 Interferon-gamma
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Zhang Peisheng
Department of Microbiology and Immunology and the Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA.
Côté Anik L
de Vries Victor C
Usherwood Edward J
Turk Mary Jo
References (50)
50 references, click to expand
  1. Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells.
    J Immunol. 2006 Mar 15;176(6):3301-5 PMID: 16517695
  2. CD8+ T cell contraction is controlled by early inflammation.
    Nat Immunol. 2004 Aug;5(8):809-17 PMID: 15247915
  3. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.
    J Exp Med. 2005 Oct 3;202(7):919-29 PMID: 16186184
  4. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.
    Nature. 2005 Mar 3;434(7029):88-93 PMID: 15744305
  5. Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection.
    J Virol. 2006 Sep;80(17):8303-15 PMID: 16912282
  6. Requirement for CD4 T cell help in generating functional CD8 T cell memory.
    Science. 2003 Apr 11;300(5617):337-9 PMID: 12690201
  7. Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses.
    J Exp Med. 2002 Dec 16;196(12):1585-92 PMID: 12486101
  8. CD8+ T-cell memory in tumor immunology and immunotherapy.
    Immunol Rev. 2006 Jun;211:214-24 PMID: 16824130
  9. Immunological consequences of tumor excision: from active immunity to immunological memory.
    Int J Cancer. 1986 Feb 15;37(2):275-81 PMID: 3943923
  10. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control.
    J Exp Med. 2003 Oct 6;198(7):1023-34 PMID: 14530375
  11. Differential contributions of central and effector memory T cells to recall responses.
    J Exp Med. 2005 Jul 4;202(1):123-33 PMID: 15983064
  12. Migratory properties of naive, effector, and memory CD8(+) T cells.
    J Exp Med. 2001 Oct 1;194(7):953-66 PMID: 11581317
  13. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity.
    Cancer Res. 2002 Mar 15;62(6):1743-50 PMID: 11912149
  14. Resection of solid tumors reverses T cell defects and restores protective immunity.
    J Immunol. 2000 Feb 15;164(4):2214-20 PMID: 10657677
  15. Understanding the generation and function of memory T cell subsets.
    Curr Opin Immunol. 2005 Jun;17(3):326-32 PMID: 15886125
  16. Molecular and functional profiling of memory CD8 T cell differentiation.
    Cell. 2002 Dec 13;111(6):837-51 PMID: 12526810
  17. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence.
    Cancer Res. 2005 Apr 15;65(8):3419-27 PMID: 15833877
  18. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
    J Immunol. 2005 Mar 1;174(5):2591-601 PMID: 15728465
  19. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
    J Exp Med. 1998 Jul 20;188(2):277-86 PMID: 9670040
  20. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
    J Immunol. 1999 Nov 15;163(10):5211-8 PMID: 10553041
  21. Cutting edge: regulation of CD8+ T cell effector population size.
    J Immunol. 2004 Sep 1;173(5):2923-7 PMID: 15322149
  22. Antigen-independent memory CD8 T cells do not develop during chronic viral infection.
    Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16004-9 PMID: 15505208
  23. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.
    J Exp Med. 2005 May 16;201(10):1591-602 PMID: 15883172
  24. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes.
    J Exp Med. 1998 Nov 2;188(9):1641-50 PMID: 9802976
  25. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    J Immunol. 2003 Dec 1;171(11):5940-7 PMID: 14634105
  26. Regulatory T cells, tumour immunity and immunotherapy.
    Nat Rev Immunol. 2006 Apr;6(4):295-307 PMID: 16557261
  27. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 PMID: 12826605
  28. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
    J Exp Med. 2003 Aug 18;198(4):569-80 PMID: 12925674
  29. CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses.
    J Exp Med. 2003 Sep 15;198(6):889-901 PMID: 12975455
  30. Multiple pathways to tumor immunity and concomitant autoimmunity.
    Immunol Rev. 2002 Oct;188:122-35 PMID: 12445286
  31. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
    J Clin Invest. 2005 Dec;115(12):3623-33 PMID: 16308572
  32. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease.
    Cancer Res. 2004 Mar 15;64(6):2205-11 PMID: 15026364
  33. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.
    J Exp Med. 2004 Sep 20;200(6):771-82 PMID: 15381730
  34. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.
    Cancer Res. 2001 Feb 1;61(3):1095-9 PMID: 11221838
  35. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
    J Immunother. 2005 Nov-Dec;28(6):582-92 PMID: 16224276
  36. Effect of chronic viral infection on epitope selection, cytokine production, and surface phenotype of CD8 T cells and the role of IFN-gamma receptor in immune regulation.
    J Immunol. 2004 Feb 1;172(3):1491-500 PMID: 14734726
  37. Naive and memory CD4+ T cell survival controlled by clonal abundance.
    Science. 2006 Apr 7;312(5770):114-6 PMID: 16513943
  38. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    J Exp Med. 1999 Aug 2;190(3):355-66 PMID: 10430624
  39. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
    Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6 PMID: 15980149
  40. Immunity to methylcholanthrene-induced sarcomas.
    J Natl Cancer Inst. 1957 Jun;18(6):769-78 PMID: 13502695
  41. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
    J Exp Med. 2001 Sep 17;194(6):823-32 PMID: 11560997
  42. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.
    J Exp Med. 1997 Feb 3;185(3):453-9 PMID: 9053445
  43. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.
    Nature. 1999 Oct 14;401(6754):708-12 PMID: 10537110
  44. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.
    Nat Immunol. 2004 Sep;5(9):927-33 PMID: 15300249
  45. Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells.
    J Immunol. 1994 Jan 15;152(2):405-12 PMID: 7904288
  46. Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity.
    J Exp Med. 1984 May 1;159(5):1312-21 PMID: 6232336
  47. Vitiligo in patients with metastatic melanoma: a good prognostic sign.
    J Am Acad Dermatol. 1983 Nov;9(5):689-96 PMID: 6643767
  48. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model.
    J Transl Med. 2006 Jun 13;4:24 PMID: 16772043
  49. Lineage relationship and protective immunity of memory CD8 T cell subsets.
    Nat Immunol. 2003 Mar;4(3):225-34 PMID: 12563257
  50. Prognostic significance of hypopigmentation in malignant melanoma.
    Arch Dermatol. 1987 Aug;123(8):1053-5 PMID: 3631983
Article Info
Journal
Cancer research
Abbr.
Cancer Res
ISSN
0008-5472
Published
2007-07-01
Pages
6468-76
Language
English
Region
United States
NLM ID
2984705R
PMCID
PMC2564800
Subset
IM
Grants
NCRR NIH HHS · P20 RR016437 · United States
NCI NIH HHS · R01 CA120777-02 · United States
NCRR NIH HHS · P20 RR016437-060010 · United States
NCRR NIH HHS · P20 RR016437-050010 · United States
NCI NIH HHS · R01 CA120777 · United States
NCRR NIH HHS · P20 RR16437 · United States
NCI NIH HHS · R01 CA120777-01 · United States
NCI NIH HHS · CA103642 · United States
NCI NIH HHS · R01 CA103642 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]